# Medial temporal lobe atrophy is associated with age and pathologies, especially small vessel disease

**Authors:** Danielle van Westen, Erik Stomrud, Luigi Lorenzini, Sebastian Palmqvist, Frederik Barkhof, Oskar Hansson, Nicola Spotorno

PMC · DOI: 10.1038/s41598-025-33602-6 · 2026-01-29

## TL;DR

This study shows that age and small vessel disease are the main factors linked to medial temporal lobe atrophy, and suggests a new age-independent method for assessing it.

## Contribution

The study introduces an age-independent cut-off for MTA that performs as well as traditional age-adjusted methods.

## Key findings

- White matter hyperintensities (WMH) mediate 32–41% of the age-MTA association.
- An age-independent MTA cut-off performed as well as age-adjusted methods in distinguishing cognitive states.
- Age and WMH are the most prominent factors associated with MTA.

## Abstract

Visual assessment of medial temporal lobe atrophy (MTA) in the clinical workup of cognitive impairment is traditionally corrected for age since MTA increases with age. In addition, common pathologies in the elderly such as amyloid, tau, alpha-synuclein and TDP-43 accumulation as well as white matter hyperintensities representing small vessel disease may affect the association between MTA and age. We investigated this in 949 cognitively unimpaired (CU) and 854 cognitively impaired (CI) individuals focusing on amyloid, tau and alpha-synuclein that at present can be measured in vivo in plasma, CSF or using PET. MTA was associated with age also when these aforementioned pathologies were accounted for. WMH was the strongest and most consistent predictor and mediated 32–41% of the association between age and MTA. Secondly, an age-independent cut-off for distinguishing between Aβ- CU and Aβ + CI was derived from 195 CU participants with low levels of pathology. Accuracy, sensitivity and specificity were comparable for our age-independent and previously published age-adjusted cut-offs. In summary, age and WMH emerged as the most prominent factors associated with MTA. Our age-independent cut-off for MTA performed in line with the best performing age-adjusted cut-off, suggesting our more parsimonious proposal could be useful in a clinical setting.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau), TARDBP (TAR DNA binding protein)

## Full-text entities

- **Genes:** SAA [NCBI Gene 6287], TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** diabetes (MESH:D003920), cerebral pathologies (MESH:D005598), amyloid (MESH:C000718787), memory impairment (MESH:D008569), AD (MESH:D000544), death (MESH:D003643), CI (MESH:D003072), neurofibrillary tangle (MESH:D055956), MTA (MESH:D004833), neurocognitive disorder (MESH:D019965), cerebrovascular disease (MESH:D002561), neuroinflammation (MESH:D000090862), hypertension (MESH:D006973), Mental Disorders (MESH:D001523), neurodegeneration (MESH:D019636), arteriolosclerosis (MESH:D050379), Dementia (MESH:D003704), WMH (MESH:D056784), Lewy body (MESH:D020961), atrophy (MESH:D001284), SVD (MESH:D059345)
- **Chemicals:** 18F-flutemetamol (MESH:C581552), MTA (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12855881/full.md

---
Source: https://tomesphere.com/paper/PMC12855881